Literature DB >> 29090087

Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series.

Ahmet Koyuncu1, Fahri Çelebi2, Erhan Ertekin3, Burcu Ece Kök2, Raşit Tükel3.   

Abstract

BACKGROUND: The relationship between social anxiety disorder (SAD) and attention-deficit/hyperactivity disorder (ADHD) is a subject which has recently become a topic of interest for research.
METHODS: In this study, 20 patients with comorbid SAD and adult ADHD who were treated with extended-release methylphenidate monotherapy were evaluated retrospectively.
RESULTS: Clinical response for both ADHD and SAD symptoms was observed in 17 of 20 patients. Overall, one patient did not respond to treatment and two patients dropped out of treatment at the beginning due to adverse effects.
CONCLUSION: Extended-release methylphenidate improved both SAD and ADHD symptoms and was generally well tolerated. Further studies are required to investigate the relationship between SAD and ADHD.

Entities:  

Keywords:  attention-deficit/hyperactivity disorder; comorbidity; extended-release methylphenidate; social anxiety disorder; treatment

Year:  2017        PMID: 29090087      PMCID: PMC5638159          DOI: 10.1177/2045125317714193

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  46 in total

1.  Prevalence of childhood ADHD among patients with Generalized Anxiety Disorder and a comparison condition, Social Phobia.

Authors:  S A Safren; G D Lanka; M W Otto; M H Pollack
Journal:  Depress Anxiety       Date:  2001       Impact factor: 6.505

Review 2.  Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder.

Authors:  Jan Haavik; Anne Halmøy; Astri J Lundervold; Ole Bernt Fasmer
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

3.  A placebo-controlled trial of risperidone in Tourette syndrome.

Authors:  L Scahill; J F Leckman; R T Schultz; L Katsovich; B S Peterson
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

4.  Social phobia.

Authors:  M R Liebowitz
Journal:  Mod Probl Pharmacopsychiatry       Date:  1987

5.  Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study.

Authors:  P Rasmussen; C Gillberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-11       Impact factor: 8.829

Review 6.  Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.

Authors:  S R Pliszka
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

7.  Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population.

Authors:  Susan L Smalley; James J McGough; Irma K Moilanen; Sandra K Loo; Anja Taanila; Hanna Ebeling; Tuula Hurtig; Marika Kaakinen; Lorie A Humphrey; James T McCracken; Teppo Varilo; May H Yang; Stanley F Nelson; Leena Peltonen; Marjo-Riitta Järvelin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-12       Impact factor: 8.829

8.  Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

Authors:  S Mannuzza; R G Klein; A Bessler; P Malloy; M LaPadula
Journal:  Arch Gen Psychiatry       Date:  1993-07

9.  Anxiety disorders in patients with Parkinson's disease.

Authors:  M B Stein; I J Heuser; J L Juncos; T W Uhde
Journal:  Am J Psychiatry       Date:  1990-02       Impact factor: 18.112

10.  Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Authors:  Lenard A Adler; Michael Liebowitz; William Kronenberger; Meihua Qiao; Richard Rubin; Millie Hollandbeck; Ahmed Deldar; Kory Schuh; Todd Durell
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

View more
  1 in total

Review 1.  ADHD and Anxiety Disorder Comorbidity in Children and Adults: Diagnostic and Therapeutic Challenges.

Authors:  Ahmet Koyuncu; Tuğba Ayan; Ezgi Ince Guliyev; Seda Erbilgin; Erdem Deveci
Journal:  Curr Psychiatry Rep       Date:  2022-01-25       Impact factor: 5.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.